Clinical Trials Logo

HCC clinical trials

View clinical trials related to HCC.

Filter by:

NCT ID: NCT04455932 Recruiting - Clinical trials for Hepatocellular Carcinoma

HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

Start date: January 2022
Phase: N/A
Study type: Interventional

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected at the early stage. Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors such as operator experience, patient body habitus and liver parenchymal heterogeneity due to chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound can be suboptimal or near non-diagnostic. Currently no guideline offers an alternative surveillance tool for patients who have suboptimal surveillance ultrasounds.

NCT ID: NCT04390724 Recruiting - Metastatic Cancer Clinical Trials

Optimizing Y90 Therapy for Radiation Lobectomy

Start date: July 17, 2020
Phase:
Study type: Observational

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

NCT ID: NCT04232722 Recruiting - HCC Clinical Trials

Sorafenib Combined With Arsenical in Treating Patients With Recurrent HCC After Liver Transplantation

HCC
Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

To analyze the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound huangdai tablets in patients with recurrent hepatocellular carcinoma after liver transplantation

NCT ID: NCT04165174 Recruiting - HCC Clinical Trials

PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

Start date: December 2019
Phase: Phase 2
Study type: Interventional

It is a trial to assess the efficacy and safety of PD-1 monoclonal antibody plus Apatinib combined with SBRT as first-line treatment in HCC with PVTT.

NCT ID: NCT03950518 Recruiting - HCC Clinical Trials

Novel Treatment of Advanced Hepatocellular Carcinoma

NTAHCC
Start date: April 10, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of arginine hydrochloride combined with Levamisole in the treatment of patients with hepatocellular carcinoma.

NCT ID: NCT03278444 Recruiting - HCC Clinical Trials

Treatment of Advanced Hepatocellular Carcinoma

TAHCC
Start date: July 18, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of arginine hydrochloride combined with trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.

NCT ID: NCT03274427 Recruiting - HCC Clinical Trials

Treatment of Intermediate-stage Hepatocellular Carcinoma

TIHCC
Start date: July 18, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with arginine hydrochloride and trimetazidine hydrochloride tablets in the treatment of patients with hepatocellular carcinoma.

NCT ID: NCT03104920 Recruiting - HCC Clinical Trials

ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy

Start date: March 27, 2017
Phase: N/A
Study type: Interventional

The worldwide introduction of multimodal enhanced recovery programs has also changed perioperative care in patients who undergo liver resection. This study will be performed to assess a comprehensive care package for patients with hepatocellular carcinoma (HCC) undergoing hepatectomy with the aim of minimal physiological disturbance in the peri-operative period. Peri-operative opioid-sparing analgesia with few gastrointestinal (GI) effects and reduced requirement for intravenous fluid therapy, early ambulation and promoted GI function recovery were centered to this plan.

NCT ID: NCT03097848 Recruiting - HCC Clinical Trials

Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma

ESCALATOR
Start date: May 4, 2017
Phase: N/A
Study type: Interventional

Radiofrequency ablation is a popular treatment for recurrent hepatocellular carcinoma (HCC),but still has a higher recurrence. Sorafenib as neo-adjuvant therapy in combination of RFA was not reported yet. There's a theoretical advantage of this combination. Hence in this study the efficacy and safety of pre-administrative Sorafenib and Latter radiofrequency ablation (RFA) in Recurrent HCC will be tested in a multicenter prospective cohort study.

NCT ID: NCT02659852 Recruiting - Pancreatic Cancer Clinical Trials

A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction

Start date: January 2016
Phase: N/A
Study type: Interventional

Malignant obstructive jaundice is a common complication of advanced stage cholangiocarcinoma, GB cancer, and pancreatic cancer. In biliary stricture by malignancy, biliary drainage with placement of self-expanding metal stent (SEMS) for palliation is the therapy of choice in these patients. On hilar biliary malignant obstruction, bilateral stent used to be inserted. There are two kinds of bilateral metal stent insertion methods in hilar biliary malignant obstruction. (Stent in stent vs. side by side) Previously, two studies was conducted to show the superiority of bilateral metal stent insertion between stent in stent and side by side. Biliary drainage and stent patency was a little superior in side by side than stent in stent. But, complication related with bilateral metal stent was increased in patients with side by side method. Another study showed that there was no significant difference between those bilateral stent insertion methods. The most important concern about side by side method is associated with portal vein thrombosis by bilateral stent diameter. Selection of proper stent insertion method in patients with hilar malignant biliary obstruction is still controversial. The purpose of this study is to investigate the patency of stent and survival of patients in side by side method (6mm sized M type) compared to stent in stent method (10mm sized LCD type) in patient with hilar malignant biliary obstruction.